| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0272-6386(99)70414-2 |
| P698 | PubMed publication ID | 10213637 |
| P2093 | author name string | Sullivan SD | |
| Hricik DE | |||
| Best JH | |||
| Hornberger J | |||
| Veenstra DL | |||
| P2860 | cites work | The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 |
| Cost-effectiveness of antihypertensive treatment: metoprolol versus thiazide diuretics | Q28372855 | ||
| The content and cost of cataract surgery | Q36767126 | ||
| Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients | Q37640702 | ||
| Corticosteroids in kidney transplant recipients. Safety issues and timing of discontinuation | Q40380386 | ||
| Prevention of transplant rejection: current treatment guidelines and future developments | Q40880337 | ||
| Cardioprotection and antihypertensive therapy: the key importance of addressing the associated coronary risk factors (the Framingham experience). | Q41145523 | ||
| Managing chronic atrial fibrillation: a Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone | Q42287672 | ||
| Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups | Q42551535 | ||
| Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation | Q43583991 | ||
| Variable effects of steroid withdrawal on blood pressure reduction in cyclosporine-treated renal transplant recipients. | Q44315423 | ||
| Rapid loss of vertebral mineral density after renal transplantation | Q44431557 | ||
| Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia | Q44719697 | ||
| Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. | Q50614072 | ||
| Model of complications of NIDDM. I. Model construction and assumptions. | Q50957725 | ||
| Effect of time elapsed since transplantation on lipid and lipoprotein abnormalities in renal transplant patients: role of maintenance prednisone and gender influence. | Q50959408 | ||
| Effects of three immunosuppressive regimens on vertebral bone density in renal transplant recipients: a prospective study. | Q50972749 | ||
| The Markov process in medical prognosis. | Q52710832 | ||
| Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression | Q57377991 | ||
| Secular trends in stroke incidence and mortality. The Framingham Study | Q57746156 | ||
| The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients | Q67585411 | ||
| A randomized prospective trial comparing cyclosporine monotherapy with triple-drug therapy in renal transplantation | Q67923351 | ||
| Complete replacement of methylprednisolone by azathioprine in cyclosporine-treated primary cadaveric renal transplant recipients | Q68123999 | ||
| The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients | Q68185394 | ||
| A controlled trial of steroids in cyclosporine-treated renal transplant recipients | Q68954522 | ||
| Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients | Q69031614 | ||
| Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model | Q69414455 | ||
| Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study | Q70460109 | ||
| Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study | Q70897761 | ||
| Diabetes mellitus after renal transplantation: characteristics, outcome, and risk factors | Q71085145 | ||
| Avascular necrosis of bone after cardiac transplantation. Prevalence and relationship to administration and dosage of steroids | Q72165847 | ||
| Bone fracture and osteodensitometry with dual energy X-ray absorptiometry in kidney transplant recipients | Q72754981 | ||
| A randomized study comparing cyclosporine alone vs double and triple therapy in renal transplants. The Italian Multicentre Study Group for Renal Transplantation (SIMTRe) | Q73277963 | ||
| FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group | Q73277986 | ||
| Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group | Q74038855 | ||
| Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients | Q74150567 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 829-839 | |
| P577 | publication date | 1999-05-01 | |
| P1433 | published in | American Journal of Kidney Diseases | Q4744250 |
| P1476 | title | Incidence and long-term cost of steroid-related side effects after renal transplantation | |
| P478 | volume | 33 |
| Q34337063 | 2,500 living donor kidney transplants: a single-center experience |
| Q35903062 | A Three-Gene Assay for Monitoring Immune Quiescence in Kidney Transplantation |
| Q44499775 | A randomized trial comparing two corticosteroid regimens combined with mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection |
| Q42643134 | A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients |
| Q43074735 | Alemtuzumab: the future of chronic inflammatory demyelinating polyradiculoneuropathy treatment? |
| Q36765942 | Antihypertensive agents and renal transplantation. |
| Q74319235 | Avascular acetabular necrosis in a renal transplant patient |
| Q46304918 | Avascular osteonecrosis after renal transplantation |
| Q46986727 | Benefits derivated from late steroid withdrawal in renal transplant recipients |
| Q38687636 | Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials |
| Q30441509 | Characteristics of adverse effects when using high dose short term steroid regimen |
| Q28282910 | Chronic inflammatory demyelinating polyneuropathies: current treatment strategies |
| Q46387294 | Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes |
| Q89456090 | Complications of total joint arthroplasty in solid organ transplant patients versus a large control group |
| Q51474388 | Correlation between insulin requirements and anti-galactose antibodies in patients with type 1 diabetes transplanted with neonatal pig islets. |
| Q33774968 | Corticosteroid administration within 2 weeks after renal transplantation affects the incidence of femoral head osteonecrosis |
| Q36029287 | Corticosteroid avoidance in pediatric renal transplantation |
| Q35902393 | Corticosteroid avoidance in pediatric renal transplantation: can it be achieved? |
| Q37522631 | Corticosteroid minimization in renal transplantation: Careful patient selection enables feasibility |
| Q36909355 | Corticosteroid withdrawal in kidney transplantation: the present status |
| Q46719599 | Corticosteroid withdrawal in simultaneous pancreas-kidney transplantation: a 3-year report |
| Q36441433 | Corticosteroid-sparing strategies in renal transplantation: are we still balancing rejection risk with improved tolerability? |
| Q46468574 | Cost of renal transplant maintenance immunosuppression: effect of control of vascular risk factors |
| Q38096463 | Current pharmacotherapeutical options for the prevention of kidney transplant rejection |
| Q38058428 | Current trends in immunosuppressive therapies for renal transplant recipients |
| Q46932531 | Diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. |
| Q41788376 | Differential expression of vascular endothelial growth factor in glucocorticoid-related osteonecrosis of the femoral head |
| Q34639731 | Early Steroid Withdrawal in Repeat Kidney Transplantation |
| Q54434558 | Early protocol biopsies in pediatric renal transplantation: interest for the adaptation of immunosuppression. |
| Q53375336 | Economic aspects of renal transplantation. |
| Q35876331 | Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk |
| Q64263285 | Effects of Telmisartan and Candesartan on the Metabolism of Lipids and Glucose in Kidney Transplant Patients: A Prospective, Randomized Crossover Study |
| Q47270130 | Effects of glucocorticoid on adipocyte size in human bone marrow |
| Q36818017 | HIV-infected kidney graft recipients managed with an early corticosteroid withdrawal protocol: clinical outcomes and messenger RNA profiles |
| Q46493646 | Hospitalizations for total hip arthroplasty after renal transplantation in the United States |
| Q38803408 | Hyperbaric oxygen therapy and osteonecrosis |
| Q35107206 | Hypertension after Kidney Transplantation: Impact, Pathogenesis and Therapy |
| Q38128162 | Hypertension after kidney transplantation: a pathophysiologic approach |
| Q36632424 | Hypertension and kidney disease: a deadly connection |
| Q46682083 | Hypertension and kidney disease: a deadly connection |
| Q58992876 | Hypertension: The Neglected Complication of Transplantation |
| Q38258155 | Immune minimization strategies in renal transplantation. |
| Q38470256 | Immunosuppressive minimization with mTOR inhibitors and belatacept. |
| Q50495936 | Impact of hybrid molecular imaging in retroperitoneal fibrosis: a systematic review. |
| Q24243851 | Interventions for preventing bone disease in kidney transplant recipients |
| Q24243926 | Interventions for preventing bone disease in kidney transplant recipients |
| Q37397103 | Kidney transplant half-life (t[1/2]) after rapid discontinuation of prednisone. |
| Q34373853 | Legal disputes over duties to disclose treatment risks to patients: a review of negligence claims and complaints in Australia |
| Q52121008 | Life satisfaction and adverse effects in renal transplant recipients: a longitudinal analysis. |
| Q24234014 | Long-term nutritional interventions for adult kidney transplant recipients |
| Q24241975 | Long-term nutritional interventions for adult kidney transplant recipients |
| Q47377350 | Loss of αB-crystallin function in zebrafish reveals critical roles in the development of the lens and stress resistance of the heart |
| Q90428781 | Low-dose Rituximab and Thymoglobulin Induction With Steroid-free Maintenance Immunosuppression and Protocol Biopsies Improves Long-term Patient and Graft Survival After Kidney Transplantation: Survival and Safety Outcomes in More Than 1100 Patients |
| Q87395242 | Methylprednisolone treatment increases the proportion of the highly suppressive HLA-DR(+)-Treg-cells in transplanted patients |
| Q37228814 | Minimization of steroids in kidney transplantation |
| Q35792373 | Multiple Adverse Effects of Systemic Corticosteroids: A Case Report |
| Q34607590 | Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection |
| Q46244695 | Near-fatal, antihypertensive medication overdose due to post-operative gastric ileus |
| Q47890626 | Nebivolol Effects on Nitric Oxide Levels, Blood Pressure, and Renal Function in Kidney Transplant Patients |
| Q34701373 | New developments in immunosuppressive therapy in renal transplantation |
| Q37763757 | Once-a-day administration of everolimus, cyclosporine, and steroid after renal transplantation: a review of the rationale |
| Q73794853 | Patient blood glucose levels before and after kidney transplantation |
| Q44101612 | Patients with high cholesterol levels benefit most from early withdrawal of corticosteroids |
| Q83364643 | Pediatric liver transplantation |
| Q33898744 | Primary care of the renal transplant patient. |
| Q35859195 | Prospective controlled protocol for three months steroid withdrawal with tacrolimus, basiliximab, and mycophenolate mofetil in renal transplant recipients |
| Q38997502 | Radiology for the surgeon. Musculoskeletal case 34. Osteonecrosis and myopathy of skeletal muscle |
| Q93063069 | Randomized, Open-Label, Phase IV, Korean Study of Kidney Transplant Patients Converting From Cyclosporine to Prolonged-Release Tacrolimus Plus Standard- or Reduced-Dose Corticosteroids |
| Q51295391 | Reconstructive surgery for kidney transplant recipients. |
| Q34069674 | Reduced fracture risk with early corticosteroid withdrawal after kidney transplant. |
| Q34547749 | Reducing adverse effects of immunosuppressive agents in kidney transplant recipients |
| Q73304286 | Risk factors for avascular bone necrosis after renal transplantation |
| Q44101405 | Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study |
| Q37356120 | Steroid elimination-who, when, how? |
| Q37760246 | Steroid minimization for sirolimus-treated renal transplant recipients |
| Q36246782 | Steroid withdrawal after renal transplantation: a retrospective cohort study. |
| Q38239572 | Steroid withdrawal in kidney allograft recipients |
| Q82289135 | Steroid withdrawal in renal transplant patients: the Irish experience |
| Q37450245 | Steroid withdrawal in simultaneous pancreas-kidney transplantation: a 7-year report |
| Q34719096 | Steroid-free immunosuppression in kidney transplantation: an editorial review |
| Q36201852 | Steroid-free immunosuppression in organ transplantation. |
| Q37318299 | Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy? |
| Q34566924 | Strategies to reduce toxicities and improve outcomes in renal transplant recipients |
| Q37354908 | Successful reduction of immunosuppression in older renal transplant recipients who exhibit donor-specific regulation |
| Q34199971 | Syndrome X following renal transplantation |
| Q38585232 | The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient |
| Q84909970 | The role of thin-layer cytology in the clinical management of renal transplantation |
| Q43142223 | To investigate the role of the nervous system of bone in steroid-induced osteonecrosis in rabbits |
| Q36876839 | Update on pharmacoeconomics in transplantation |
| Q34421844 | Urinary and dietary sodium and potassium associated with blood pressure control in treated hypertensive kidney transplant recipients: an observational study |
Search more.